CCR 20th Anniversary Commentary: A Chimeric Antibody, C225, Inhibits EGFR Activation and Tumor Growth

被引：23
|
作者：
Mendelsohn, John [1 ]
Prewett, Marie [2 ]
Rockwell, Patricia [3 ]
Goldstein, Neil I. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] CUNY Hunter Coll, New York, NY 10021 USA
[4] Helio Genet, E Hanover, NJ USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 02期
关键词：
RECEPTOR MONOCLONAL-ANTIBODY; METASTATIC COLORECTAL-CANCER; SQUAMOUS-CELL CARCINOMA; PHASE-I; CETUXIMAB; COMBINATION; RESISTANCE; NECK; HEAD;
D O I：
10.1158/1078-0432.CCR-14-2491
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Murine mAb 225 was effective against the EGFR tyrosine kinase and inhibited tumor growth in preclinical studies. A phase I trial showed safety, tumor localization, and satisfactory pharmacokinetics. Human: murine chimeric C225 retained biologic activity, which was essential for the conduct of subsequent combination therapy trials and eventual regulatory approval.
引用
收藏
页码：227 / 229
页数：3
相关论文
共 37 条
  • [21] CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer
    Allen, Clint T.
    Conley, Barbara
    Sunwoo, John B.
    Van Waes, Carter
    CLINICAL CANCER RESEARCH, 2015, 21 (05) : 942 - 943
  • [22] CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later?
    Antonescu, Cristina R.
    DeMatteo, Ronald P.
    CLINICAL CANCER RESEARCH, 2015, 21 (15) : 3363 - 3365
  • [23] Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice
    Prewett, M
    Rothman, M
    Waksal, H
    Feldman, M
    Bander, NH
    Hicklin, DJ
    CLINICAL CANCER RESEARCH, 1998, 4 (12) : 2957 - 2966
  • [24] CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015-Still in the Ballpark
    Narod, Steven A.
    Dent, Rebecca A.
    Foulkes, William D.
    CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3813 - +
  • [25] CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux
    Davar, Diwakar
    Kirkwood, John M.
    CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5412 - 5414
  • [26] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
    Baselga, J
    Pfister, D
    Cooper, MR
    Cohen, R
    Burtness, B
    Bos, M
    D'Andrea, G
    Seidman, A
    Norton, L
    Gunnett, K
    Falcey, J
    Anderson, V
    Waksal, H
    Mendelsohn, J
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) : 904 - 914
  • [27] CCR 20th Anniversary Commentary: Autologous T Cells-The Ultimate Personalized Drug for the Immunotherapy of Human Cancer
    Rosenberg, Steven A.
    CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5409 - 5411
  • [28] CCR 20th Anniversary Commentary: In Search of Cetuximab's First Indication-Combination Therapy with Irinotecan in Colorectal Cancer
    Hicklin, Daniel J.
    CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1505 - 1507
  • [29] CCR 20th Anniversary Commentary: Immune-Related Response Criteria-Capturing Clinical Activity in Immuno-Oncology
    Hoos, Axel
    Wolchok, Jedd D.
    Humphrey, Rachel W.
    Hodi, F. Stephen
    CLINICAL CANCER RESEARCH, 2015, 21 (22) : 4989 - 4991
  • [30] Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
    Perrotte, P
    Matsumoto, T
    Inoue, K
    Kuniyasu, H
    Eve, BY
    Hicklin, DJ
    Radinsky, R
    Dinney, CPN
    CLINICAL CANCER RESEARCH, 1999, 5 (02) : 257 - 265
1234